Skip to main content
. Author manuscript; available in PMC: 2014 May 6.
Published in final edited form as: Mol Pharm. 2013 Apr 24;10(5):1988–1997. doi: 10.1021/mp400007k

Figure 6.

Figure 6

(A) shows PDT schematic for the in vivo studies, (B) shows OPS-measured skin concentrations of Pc 4 over 5 days (with the first 6 hrs in magnified inset) while (C) shows OPS-measured tumor concentrations of Pc 4 over 5 days (with the first 6 hrs in magnified inset) when delivered intravenously by the different formulations; the EGFR-targeted Pc 4 formulation shows higher intra-tumoral uptake and retention of Pc 4 over time compared to the non-targeted and the Intralipid-based Pc 4 formulations.